Measuring the impact of steroid therapy on health-related quality of life in patients with rheumatic diseases: international development of a glucocorticoid treatment-specific patient-reported outcome measure.

"an iterative process of refinement and reduction of items through patient partner review two rounds of cognitive interviews and incorporation of the translatability assessment findings (see supplementary data s1 available at rheumatology online) was then completed by the group (j c r j d and s b and patient partners c s and p r).; a linguistic evaluation has been performed with adaptations made to the questionnaire items to ensure formal translations into other languages will be possible in the future ( supplementary data s1 available at rheumatology online)."

"Disclosure statement : S.B. reports: Steroid PRO research start-up grant from Above & Beyond Bristol Hospitals Charity; Steroid PRO research grant from Vifor Pharma; Steroid PRO cross-condition validation study research grant from Sanofi. M.A.S. reports: Steroid PRO research start-up grant from Above & Beyond Bristol Hospitals Charity; Steroid PRO research grant from Vifor Pharma. J.D. reports: GCA PRO funding from NIHR RfPB; consultancy for Oxford University Innovation (Clinical Outcomes); she occasionally receives royalty monies, directly, from commercial licenses issued for Patient-Reported Outcome Measures where she was an ‘Author’/inventor. M.N. reports: Steroid PRO research grant from Vifor Pharma; GCA PRO funding from NIHR RfPB; Steroid PRO cross-condition validation study research grant from Sanofi. C.A. reports: Steroid PRO research start-up grant from Above & Beyond Bristol Hospitals Charity; Steroid PRO research grant from Vifor Pharma; GCA PRO funding from NIHR RfPB. E.D. reports: Steroid PRO research start-up grant from Above & Beyond Bristol Hospitals Charity; Steroid PRO research grant from Vifor Pharma; GCA PRO funding from NIHR RfPB; Steroid PRO cross-condition validation study research grant from Sanofi. I.N.-M. reports: NIH-NIAMS K23; Innovative Research Award from Rheumatology Research Foundation. J.T. reports: research grant funding from Vifor Pharma; education grant from Vifor Pharma. S.L.M. reports: consultancy on behalf of her institution for Roche/Chugai, Sanofi, AbbVie, AstraZeneca; speaking/lecturing on behalf of her institution for Roche/Chugai, Pfizer and Vifor Pharma; Investigator on clinical trials for Sanofi and GSK; Chief Investigator on STERLING-PMR trial, funded by NIHR; Patron of the charity PMRGCAuk. No personal remuneration was received for any of the above activities. Support from Roche/Chugai to attend EULAR2019 in person and from Pfizer to attend ACR Convergence 2021 virtually. S.G. reports: research support from Novartis; AMP-AIM funding from NIH; Refractory RA funding from Arthritis Foundation; consultancy for UCB; speaking fees from NYU, Case Western, ACR Rheumatology Courses; board participation for UCB; ACR Guideline subcommittee chair. C.H. reports: research grant from Arthritis Australia; Chief Investigator on Sterling-PMR trial, funded by NHMRC; Medical Advisor and Board Member; Arthritis South Australia AND Board Member, Australia New Zealand Vasculitis Society. J.C.R. reports: Steroid PRO research start-up grant from Above & Beyond Bristol Hospitals Charity; Steroid PRO research grant from Vifor Pharma; Steroid PRO cross-condition validation study research grant from Sanofi; GCA PRO funding from NIHR RfPB; Consultancy for Vifor Pharma; Speaking fees from Vifor Pharma."

"Funding This work was supported by: Above and Beyond Bristol Hospitals charity, University Hospitals Bristol NHS Foundation Trust [2019-Spr-07]; and QR Funding, University of the West of England, Bristol [UWE-QR-2021]. The Australian portion of this work was supported by: Australian Rheumatology Association Project Grant, administered by Arthritis Australia. Disclosure statement: S.B. reports: Steroid PRO research start-up grant from Above & Beyond Bristol Hospitals Charity; Steroid PRO research grant from Vifor Pharma; Steroid PRO cross-condition validation study research grant from Sanofi. M.A.S. reports: Steroid PRO research start-up grant from Above & Beyond Bristol Hospitals Charity; Steroid PRO research grant from Vifor Pharma. J.D. reports: GCA PRO funding from NIHR RfPB; consultancy for Oxford University Innovation (Clinical Outcomes); she occasionally receives royalty monies, directly, from commercial licenses issued for Patient-Reported Outcome Measures where she was an ‘Author’/inventor. M.N. reports: Steroid PRO research grant from Vifor Pharma; GCA PRO funding from NIHR RfPB; Steroid PRO cross-condition validation study research grant from Sanofi. C.A. reports: Steroid PRO research start-up grant from Above & Beyond Bristol Hospitals Charity; Steroid PRO research grant from Vifor Pharma; GCA PRO funding from NIHR RfPB. E.D. reports: Steroid PRO research start-up grant from Above & Beyond Bristol Hospitals Charity; Steroid PRO research grant from Vifor Pharma; GCA PRO funding from NIHR RfPB; Steroid PRO cross-condition validation study research grant from Sanofi. I.N.-M. reports: NIH-NIAMS K23; Innovative Research Award from Rheumatology Research Foundation. J.T. reports: research grant funding from Vifor Pharma; education grant from Vifor Pharma. S.L.M. reports: consultancy on behalf of her institution for Roche/Chugai, Sanofi, AbbVie, AstraZeneca; speaking/lecturing on behalf of her institution for Roche/Chugai, Pfizer and Vifor Pharma; Investigator on clinical trials for Sanofi and GSK; Chief Investigator on STERLING-PMR trial, funded by NIHR; Patron of the charity PMRGCAuk. No personal remuneration was received for any of the above activities. Support from Roche/Chugai to attend EULAR2019 in person and from Pfizer to attend ACR Convergence 2021 virtually. S.G. reports: research support from Novartis; AMP-AIM funding from NIH; Refractory RA funding from Arthritis Foundation; consultancy for UCB; speaking fees from NYU, Case Western, ACR Rheumatology Courses; board participation for UCB; ACR Guideline subcommittee chair. C.H. reports: research grant from Arthritis Australia; Chief Investigator on Sterling-PMR trial, funded by NHMRC; Medical Advisor and Board Member; Arthritis South Australia AND Board Member, Australia New Zealand Vasculitis Society. J.C.R. reports: Steroid PRO research start-up grant from Above & Beyond Bristol Hospitals Charity; Steroid PRO research grant from Vifor Pharma; Steroid PRO cross-condition validation study research grant from Sanofi; GCA PRO funding from NIHR RfPB; Consultancy for Vifor Pharma; Speaking fees from Vifor Pharma."